These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 11858504

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Heat inactivation of extended half-life factor VIII concentrates.
    Fylling KA, Tange JI, Chen D, Pruthi RK.
    Haemophilia; 2019 Mar; 25(2):e130-e131. PubMed ID: 30748064
    [No Abstract] [Full Text] [Related]

  • 23. [Porcine factor VIII].
    De Juan MJ, Montoro JB, Tusell JM.
    Sangre (Barc); 1991 Jun; 36(3):217-20. PubMed ID: 1948542
    [No Abstract] [Full Text] [Related]

  • 24. The use of porcine factor VIII in France.
    Negrier C.
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):29-32. PubMed ID: 7939770
    [No Abstract] [Full Text] [Related]

  • 25. Porcine factor VIII: past, present and future.
    Hay CR.
    Haematologica; 2000 Oct; 85(10 Suppl):21-4; discussion 24-5. PubMed ID: 11187865
    [Abstract] [Full Text] [Related]

  • 26. Factor VIII haplotypes in severe hemophilia A patients in India.
    Pinto P, Ghosh K, Shetty S.
    Ann Hematol; 2013 Jul; 92(7):999-1000. PubMed ID: 23262994
    [No Abstract] [Full Text] [Related]

  • 27. The evidence behind inhibitor treatment with porcine factor VIII.
    Lee CA.
    Pathophysiol Haemost Thromb; 2002 Jul; 32 Suppl 1():5-8. PubMed ID: 12214138
    [Abstract] [Full Text] [Related]

  • 28. Haemostatic response to factor VIII administration in patients with haemophilia A measured by thrombin generation and correlation with factor concentrate use.
    Hugenholtz GC, Luddington R, Baglin T.
    Haemophilia; 2016 Jan; 22(1):e42-5. PubMed ID: 26388112
    [No Abstract] [Full Text] [Related]

  • 29. Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations.
    Longo G, Messori A, Morfini M, Baudo F, Ciavarella N, Cinotti S, Filimberti E, Giustarini G, Molinari AC, Ferrini PR.
    Am J Hematol; 1989 Mar; 30(3):140-9. PubMed ID: 2492760
    [Abstract] [Full Text] [Related]

  • 30. Switching from current factor VIII (FVIII) to longer acting FVIII concentrates--what is the real potential benefit?
    Carcao M.
    Haemophilia; 2015 May; 21(3):297-299. PubMed ID: 25854624
    [No Abstract] [Full Text] [Related]

  • 31. Comparison of anti-human and anti-porcine factor VIII inhibitor levels in 63 patients with severe haemophilia A. A French Multicentric Study.
    Fiks-Sigaud M, Bendelac L, Parquet A, Verroust F, Torchet MF, Berthier AM, Fressinaud E, Guerois C, Aillaud MF, Boneu B.
    Vox Sang; 1993 May; 64(4):210-4. PubMed ID: 8517049
    [Abstract] [Full Text] [Related]

  • 32. Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.
    Repessé Y, Costa C, Palla R, Moshai EF, Borel-Derlon A, D'Oiron R, Rothschild C, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Oldenburg J, Pavlova A, Rosendaal FR, Peyvandi F, Kaveri SV, Lacroix-Desmazes S.
    Haematologica; 2019 Aug; 104(8):e369-e372. PubMed ID: 30705098
    [No Abstract] [Full Text] [Related]

  • 33. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects.
    Hay CR, Lozier JN, Lee CA, Lafan M, Tradati H, Santagostino E, Ciavarella N, Schiavoni M, Fukui H, Yoshioka A.
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):20-5. PubMed ID: 7939768
    [No Abstract] [Full Text] [Related]

  • 34. Immune response induced by porcine factor VIII in severe hemophiliacs with antibody to F VIII.
    Verroust F, Allain JP.
    Thromb Haemost; 1982 Oct 29; 48(2):238. PubMed ID: 6817447
    [No Abstract] [Full Text] [Related]

  • 35. Current status of clinical studies of recombinant factor VIII (recombinate) in patients with hemophilia A. Recombinate Study Group.
    Bray GL.
    Transfus Med Rev; 1992 Oct 29; 6(4):252-5. PubMed ID: 1421824
    [No Abstract] [Full Text] [Related]

  • 36. Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia.
    Lange D, Lazerson J.
    Wis Med J; 1982 Feb 29; 81(2):28-31. PubMed ID: 6803446
    [No Abstract] [Full Text] [Related]

  • 37. Design and assessment of clinical trials on continuous infusion.
    Schulman S, Martinowitz U.
    Blood Coagul Fibrinolysis; 1996 Mar 29; 7 Suppl 1():S7-9. PubMed ID: 8735790
    [Abstract] [Full Text] [Related]

  • 38. Lyophilized cryoprecipitate for children with hemophilia A.
    Nuchprayoon I, Sahasittiwat S, Kittikalayawong A, Chantanakajornfung A.
    J Med Assoc Thai; 2002 Jun 29; 85 Suppl 1():S293-7. PubMed ID: 12188426
    [Abstract] [Full Text] [Related]

  • 39. Investigation of porcine parvovirus among persons with hemophilia receiving Hyate:C porcine factor VIII concentrate.
    Soucie JM, Erdman DD, Evatt BL, Anderson LJ, Török TJ, El-Jamil M, Barnhart E, Tepper M, Burrill HN, Pickett AM, Mengeling WL.
    Transfusion; 2000 Jun 29; 40(6):708-11. PubMed ID: 10864993
    [Abstract] [Full Text] [Related]

  • 40. Development of an inhibitor in a man with mild haemophilia A.
    Evans MS, Eyster ME.
    Haemophilia; 2017 Sep 29; 23(5):e473-e474. PubMed ID: 28750480
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.